title: 5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro.
abstract: 1. 5-Hydroxytryptamine (5-HT) is known to produce a number of different effects in the gastrointestinal tract of various species, and has been proposed to play a key role in a number of intestinal disorders in man, including irritable bowel syndrome (IBS), although the receptors involved have yet to be established. The aim of the present study was to investigate the distribution and function of 5-HT(2B) receptors in human colon, and to establish their possible role in the aetiology of IBS. 2. The distribution of 5-HT(2B) receptor mRNA and protein were investigated by quantitative RT - PCR, Western analysis and immunocytochemistry. High levels of both mRNA and protein for 5-HT(2B) receptors were found throughout the human gastrointestinal tract, and in particular in colon, where 5-HT(2B) receptors were found predominantly in the longitudinal and circular smooth muscle layers within the muscularis externa, and in the myenteric nerve plexus lying between these two layers. 3. Electrical field stimulation of longitudinal muscle preparations of human colon mounted in organ baths resulted in neuronally-mediated contractile responses, that were significantly potentiated by application of 5-HT (up to 10(-7) M), with a pEC(50) of 8.2 +/- 0.1 (n=49 donors). The response to 5-HT was inhibited by a number of selective 5-HT(2B) receptor antagonists. 4. This study has shown for the first time that, in contrast to animal studies, the excitatory effects of 5-HT in human colon are mediated by 5-HT(2B) receptors. It is proposed that these receptors contribute to the putative 5-HT-induced colonic smooth muscle hypersensitivity associated with IBS.
authors.affiliation: Pharmagene Laboratories Ltd., Orchard Road, Royston, Hertfordshire, SG8 5HD, UK. richard.borman@pharmagene.com
authors.forename: R A
authors.initials: RA
authors.lastname: Borman
authors.forename: N S
authors.initials: NS
authors.lastname: Tilford
authors.forename: D W
authors.initials: DW
authors.lastname: Harmer
authors.forename: N
authors.initials: N
authors.lastname: Day
authors.forename: E S
authors.initials: ES
authors.lastname: Ellis
authors.forename: R L G
authors.initials: RL
authors.lastname: Sheldrick
authors.forename: J
authors.initials: J
authors.lastname: Carey
authors.forename: R A
authors.initials: RA
authors.lastname: Coleman
authors.forename: G S
authors.initials: GS
authors.lastname: Baxter
mesh_terms: D003106:Colon / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D003109:Colonic Diseases, Functional / Q000378:metabolism / Q000503:physiopathology; D004558:Electric Stimulation; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000502:physiology; D015870:Gene Expression / Q000502:physiology; D006801:Humans; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000502:physiology*; D012333:RNA, Messenger / Q000032:analysis; D044403:Receptor, Serotonin, 5-HT2B; D011985:Receptors, Serotonin / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D012701:Serotonin / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology
chemical_list: D012333:RNA, Messenger; D044403:Receptor, Serotonin, 5-HT2B; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D012701:Serotonin